Lumos Diagnostics Holdings (ASX:LDX) received confirmation of Medicare reimbursement coverage in the US from two additional Medicare administrative contractors, First Coast Service Options and Noridian Healthcare Solutions, according to a Wednedsay Australian bourse filing.
The firm's FebriDx point-of-care diagnostic test will be included in the Medicare fee schedule of the contractors at at $41.38 per test retroactively from April 1.
Its shares jumped 4% in recent trading on Wednesday.